Form 4: NovoCure Director Jeryl L. Hilleman Reports Stock and Option Awards
SEC Form 4
Director Jeryl L. Hilleman reports the acquisition of restricted stock units and stock options in NovoCure Ltd.
Summary
- Jeryl L. Hilleman, a director of NovoCure Ltd, reported transactions involving the company's securities on June 5, 2024.
- Hilleman acquired 4,053 restricted stock units at a price of $0.00.
- Following this transaction, Hilleman beneficially owns 6,590 restricted stock units.
- Hilleman also acquired options to buy 6,229 ordinary shares at an exercise price of $23.13.
- These options will fully vest and become exercisable on the earlier of June 4, 2025, or the day immediately preceding the Company's 2025 annual general meeting of shareholders.
- After the transaction, Hilleman directly owns 6,229 derivative securities.
Sentiment
Score: 6
Explanation: The document is a standard SEC filing detailing stock and option awards, which is neutral in sentiment. It reflects typical executive compensation practices.
Positives
- The grant of restricted stock units and stock options to a director aligns their interests with those of shareholders.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The granting of stock options and restricted stock units can incentivize the director to act in the best interests of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: acquisition of restricted stock units and stock options. |
| 06/04/2034 | Expiration date of the stock options. |
| 2025 | Restricted stock units and stock options vest on the earlier of the first anniversary of the grant date or the day immediately preceding the Company's 2025 annual general meeting of shareholders. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.